Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS.

Transplantation and cellular therapy·2026

Same author

Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.

Haematologica·2026

Same author

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026

Same author

Two-Stage Double-Arm Trial Optimal Design of Restricted Mean Survival Time With Sculpted Critical Region.

Statistics in medicine·2026

Same author

Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Bayesian Integrated Learning of Longitudinal Dose-Response Relationships via Decentralized Clinical Trials.

Statistics in medicine·2025

Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026

Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026

Same journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026

Same journal

Beyond Fixed Thresholds: Optimizing Summaries of Wearable Device Data via Piecewise Linearization of Quantile Functions.

Statistics in medicine·2026

Same journal

A Causal Framework for Evaluating the Total Effect of Strategies Aiming to Expand Screening and to Improve Outcomes.

Statistics in medicine·2026

Same journal

Causal Effects on Nonterminal Event Time With Application to Antibiotic Usage and Future Resistance.

Statistics in medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 22, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

BAR12: Bayesian Autoregressive Phase 1-2 Design for Cell Therapy Trials With Manufacturing Changes.

Cheng-Han Yang¹, Peter F Thall¹, David Marin²

¹Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Statistics in Medicine

|April 20, 2026

Summary

This summary is machine-generated.

This study introduces a new Bayesian statistical design for early-phase cell therapy trials. The Bayesian AutoRegressive Phase 1-2 (BAR12) design effectively manages manufacturing changes, improving dose selection and patient safety.

More Related Videos

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Apr 22, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Biostatistics
Clinical Trial Design
Cell Therapy Manufacturing

Background:

Early-phase cell therapy trials often require manufacturing "tweaks" to optimize product quality.
These modifications can alter dose-response distributions, complicating trial design.
Existing statistical methods may not adequately account for such in-trial changes.

Purpose of the Study:

To propose a novel statistical design for phase 1-2 cell therapy trials that accommodates manufacturing tweaks.
To ensure that dose-finding and safety monitoring remain robust despite product modifications.
To improve the efficiency and accuracy of dose selection in adaptive trial settings.

Main Methods:

Development of the Bayesian AutoRegressive Phase 1-2 (BAR12) design.
Utilizes a first-order autoregressive model with spike-and-slab priors.
Incorporates pre- and post-tweak toxicity and efficacy parameter distributions.

Main Results:

Simulations demonstrate BAR12's superior operating characteristics compared to conventional designs.
BAR12 shows higher probabilities of correct dose selection.
Efficiently allocates more patients to optimal doses and monitors for safety.

Conclusions:

The BAR12 design offers a robust statistical framework for cell therapy trials with manufacturing modifications.
It enhances the ability to identify optimal and safe doses.
Facilitates adaptive trial management without compromising statistical integrity.